127 related articles for article (PubMed ID: 36542958)
1. Discovery and characterization of orally bioavailable 4-chloro-6-fluoroisophthalamides as covalent PPARG inverse-agonists.
Orsi DL; Ferrara SJ; Siegel S; Friberg A; Bouché L; Pook E; Lienau P; Bluck JP; Lemke CT; Akcay G; Stellfeld T; Meyer H; Pütter V; Holton SJ; Korr D; Jerchel-Furau I; Pantelidou C; Strathdee CA; Meyerson M; Eis K; Goldstein JT
Bioorg Med Chem; 2023 Jan; 78():117130. PubMed ID: 36542958
[TBL] [Abstract][Full Text] [Related]
2. Discovery and Structure-Based Design of Potent Covalent PPARγ Inverse-Agonists
Orsi DL; Pook E; Bräuer N; Friberg A; Lienau P; Lemke CT; Stellfeld T; Brüggemeier U; Pütter V; Meyer H; Baco M; Tang S; Cherniack AD; Westlake L; Bender SA; Kocak M; Strathdee CA; Meyerson M; Eis K; Goldstein JT
J Med Chem; 2022 Nov; 65(21):14843-14863. PubMed ID: 36270630
[TBL] [Abstract][Full Text] [Related]
3. Role of peroxisome proliferator activated receptor-gamma in bacillus Calmette-Guérin bladder cancer therapy.
Langle Y; Lodillinsky C; Belgorosky D; Sandes EO; Eiján AM
J Urol; 2012 Dec; 188(6):2384-90. PubMed ID: 23088980
[TBL] [Abstract][Full Text] [Related]
4. CORR® ORS Richard A. Brand Award: Disruption in Peroxisome Proliferator-Activated Receptor-γ (PPARG) Increases Osteonecrosis Risk Through Genetic Variance and Pharmacologic Modulation.
Wyles CC; Paradise CR; Houdek MT; Slager SL; Terzic A; Behfar A; van Wijnen AJ; Sierra RJ
Clin Orthop Relat Res; 2019 Aug; 477(8):1800-1812. PubMed ID: 31135556
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer-associated skeletal muscle mitochondrial dysfunction and lipid accumulation is reversed by PPARG.
Wilson HE; Stanton DA; Rellick S; Geldenhuys W; Pistilli EE
Am J Physiol Cell Physiol; 2021 Apr; 320(4):C577-C590. PubMed ID: 33439777
[TBL] [Abstract][Full Text] [Related]
6. UHRF1 coordinates peroxisome proliferator activated receptor gamma (PPARG) epigenetic silencing and mediates colorectal cancer progression.
Sabatino L; Fucci A; Pancione M; Carafa V; Nebbioso A; Pistore C; Babbio F; Votino C; Laudanna C; Ceccarelli M; Altucci L; Bonapace IM; Colantuoni V
Oncogene; 2012 Dec; 31(49):5061-72. PubMed ID: 22286757
[TBL] [Abstract][Full Text] [Related]
7. Structural insight into PPARgamma activation through covalent modification with endogenous fatty acids.
Waku T; Shiraki T; Oyama T; Fujimoto Y; Maebara K; Kamiya N; Jingami H; Morikawa K
J Mol Biol; 2009 Jan; 385(1):188-99. PubMed ID: 18977231
[TBL] [Abstract][Full Text] [Related]
8. Biochemical and structural basis for the pharmacological inhibition of nuclear hormone receptor PPARγ by inverse agonists.
Irwin S; Karr C; Furman C; Tsai J; Gee P; Banka D; Wibowo AS; Dementiev AA; O'Shea M; Yang J; Lowe J; Mitchell L; Ruppel S; Fekkes P; Zhu P; Korpal M; Larsen NA
J Biol Chem; 2022 Nov; 298(11):102539. PubMed ID: 36179791
[TBL] [Abstract][Full Text] [Related]
9. Regulation of expression and role of peroxisome proliferator-activated receptors (PPARs) in luminal epithelial and stromal cells of the porcine endometrium.
Blitek A; Szymanska M
Theriogenology; 2019 Mar; 127():88-101. PubMed ID: 30677596
[TBL] [Abstract][Full Text] [Related]
10. Distinct gene regulatory programs define the inhibitory effects of liver X receptors and PPARG on cancer cell proliferation.
Savic D; Ramaker RC; Roberts BS; Dean EC; Burwell TC; Meadows SK; Cooper SJ; Garabedian MJ; Gertz J; Myers RM
Genome Med; 2016 Jul; 8(1):74. PubMed ID: 27401066
[TBL] [Abstract][Full Text] [Related]
11. Computer-aided discovery, validation, and mechanistic characterization of novel neolignan activators of peroxisome proliferator-activated receptor gamma.
Fakhrudin N; Ladurner A; Atanasov AG; Heiss EH; Baumgartner L; Markt P; Schuster D; Ellmerer EP; Wolber G; Rollinger JM; Stuppner H; Dirsch VM
Mol Pharmacol; 2010 Apr; 77(4):559-66. PubMed ID: 20064974
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of peroxisome proliferator activated receptor γ regulation by non-steroidal anti-inflammatory drugs.
Puhl AC; Milton FA; Cvoro A; Sieglaff DH; Campos JC; Bernardes A; Filgueira CS; Lindemann JL; Deng T; Neves FA; Polikarpov I; Webb P
Nucl Recept Signal; 2015; 13():e004. PubMed ID: 26445566
[TBL] [Abstract][Full Text] [Related]
13. Effect of rosiglitazone on peroxisome proliferator-activated receptor gamma gene expression in human adipose tissue is limited by antiretroviral drug-induced mitochondrial dysfunction.
Mallon PW; Sedwell R; Rogers G; Nolan D; Unemori P; Hoy J; Samaras K; Kelleher A; Emery S; Cooper DA; Carr A;
J Infect Dis; 2008 Dec; 198(12):1794-803. PubMed ID: 18954260
[TBL] [Abstract][Full Text] [Related]
14. Structural Biology Inspired Development of a Series of Human Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) Ligands: From Agonist to Antagonist.
Miyachi H
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835351
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of selected 3D virtual screening tools for the prospective identification of peroxisome proliferator-activated receptor (PPAR) γ partial agonists.
Kaserer T; Obermoser V; Weninger A; Gust R; Schuster D
Eur J Med Chem; 2016 Nov; 124():49-62. PubMed ID: 27560282
[TBL] [Abstract][Full Text] [Related]
16. Editor's Highlight: Screening ToxCast Prioritized Chemicals for PPARG Function in a Human Adipose-Derived Stem Cell Model of Adipogenesis.
Foley B; Doheny DL; Black MB; Pendse SN; Wetmore BA; Clewell RA; Andersen ME; Deisenroth C
Toxicol Sci; 2017 Jan; 155(1):85-100. PubMed ID: 27664422
[TBL] [Abstract][Full Text] [Related]
17. Peroxisome proliferator-activated receptor gamma in bladder cancer: a promising therapeutic target.
Mansure JJ; Nassim R; Kassouf W
Cancer Biol Ther; 2009 Apr; 8(7):6-15. PubMed ID: 19417560
[TBL] [Abstract][Full Text] [Related]
18. INT131: a selective modulator of PPAR gamma.
Motani A; Wang Z; Weiszmann J; McGee LR; Lee G; Liu Q; Staunton J; Fang Z; Fuentes H; Lindstrom M; Liu J; Biermann DH; Jaen J; Walker NP; Learned RM; Chen JL; Li Y
J Mol Biol; 2009 Mar; 386(5):1301-11. PubMed ID: 19452630
[TBL] [Abstract][Full Text] [Related]
19. Genomic Activation of
Goldstein JT; Berger AC; Shih J; Duke FF; Furst L; Kwiatkowski DJ; Cherniack AD; Meyerson M; Strathdee CA
Cancer Res; 2017 Dec; 77(24):6987-6998. PubMed ID: 28923856
[TBL] [Abstract][Full Text] [Related]
20. hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferator-activated receptor-gamma agonists.
Li Y; Wen X; Spataro BC; Hu K; Dai C; Liu Y
J Am Soc Nephrol; 2006 Jan; 17(1):54-65. PubMed ID: 16291834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
